Abstract:Background Programmed necrosis/necroptosis is an emerging form of cell death that plays important roles in mammalian development and the immune system. The pro-necrotic kinases in the receptor interacting protein (RIP) family are crucial mediators of programmed necrosis. Recent advances in necrosis research have been greatly aided by the identification of chemical inhibitors that block programmed necrosis. Necrostatin-1 (Nec-1) and its derivatives were previously shown to target the pro-necrotic kinase RIP1/RIPK1. The protective effect conferred by Nec-1 and its derivatives in many experimental model systems was often attributed to the inhibition of RIP1 function. Methodology/Principal Findings We compared the effect of Nec-1 and siRNA-mediated silencing of RIP1 in the murine fibrosarcoma cell line L929. Treatment of L929 cells with the pan-caspase inhibitor zVAD-fmk or exogenous TNF induces necrosis. Strikingly, we found that siRNA-mediated silencing of RIP1 inhibited zVAD-fmk induced necrosis, but not TNF-induced necrosis. TNF-induced cell death in RIP1 knocked down L929 cells was inhibited by Nec-1, but not the caspase inhibitor zVAD-fmk. We found that PKA-C§ expression, but not Jnk or Erk activation, was moderately inhibited by Nec-1. Moreover, we found that Nec-1 inhibits proximal T cell receptor signaling independent of RIP1, leading to inhibition of T cell proliferation. Conclusions/Significance Our results reveal that besides RIP1, Nec-1 also targets other factors crucial for necrosis induction in L929 cells. In addition, high doses of Nec-1 inhibit other signal transduction pathways such as that for T cell receptor activation. These results highlight the importance to independently validate results obtained using Nec-1 with other approaches such as siRNA-mediated gene silencing. We propose that some of the previous published results obtained using Nec-1 should be re-evaluated in light of our findings.

Structural Basis of RIP1 Inhibition by Necrostatins.

Inhibition of Receptor-Interacting Protein 3 Upregulation and Nuclear Translocation Involved in Necrostatin-1 Protection Against Hippocampal Neuronal Programmed Necrosis Induced by Ischemia/reperfusion Injury.

Structural Insights into RIP3-Mediated Necroptotic Signaling

RIP1-Dependent and Independent Effects of Necrostatin-1 in Necrosis and T Cell Activation

Profiling of Small-Molecule Necroptosis Inhibitors Based on the Subpockets of Kinase-Ligand Interactions.

Identification of the Raf Kinase Inhibitor TAK‐632 and Its Analogues As Potent Inhibitors of Necroptosis by Targeting RIPK1 and RIPK3

RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development

Ring Closure Strategy Leads to Potent RIPK3 Inhibitors

Diverse sequence determinants control human and mouse receptor interacting protein 3 (RIP3) and mixed lineage kinase domain-like (MLKL) interaction in necroptotic signaling.

Necroptosis in health and diseases

Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1

Necrostatin-1 Prevents Necroptosis in Brains after Ischemic Stroke Via Inhibition of RIPK1-Mediated RIPK3/MLKL Signaling

RIP3 Induces Apoptosis Independent of Pronecrotic Kinase Activity.

RIP3-mediated necroptosis is regulated by inter-filament assembly of RIP homotypic interaction motif

Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.

Discovery of Potent Necroptosis Inhibitors Targeting RIPK1 Kinase Activity for the Treatment of Inflammatory Disorder and Cancer Metastasis.

Pleiotropic, non-cell death-associated effects of inhibitors of receptor-interacting protein kinase 1 in the heart

Targeting RIPK3 Oligomerization Blocks Necroptosis Without Inducing Apoptosis.

Necroptosis inhibitors: mechanisms of action and therapeutic potential

Regulation of Ripk3-And Rhim-Dependent Necroptosis by the Proteasome

Synthesis and Characterization of Potent RIPK3 Inhibitors Based on a Tricyclic Scaffold.